Cytokines and cognition - The case for a head-to-toe inflammatory paradigm

Journal of the American Geriatrics Society

Volumn 50, Issue 12, 2002, Pages 2041-2056

  Wilson, Craig J ^a   Finch, Caleb E ^b   Cohen, Harvey J ^c,d  

^a St Vincent Hospitals and Health Services   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cognition; Cytokines; Inflammation

Indexed keywords

CYTOKINE; TRACE ELEMENT;

AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CELL FUNCTION; CHOLINERGIC ACTIVITY; COGNITION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DEPRESSION; DOPAMINERGIC SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFLAMMATION; NEUROPHYSIOLOGY; NONHUMAN; PROTEIN FUNCTION; SLEEP; STRESS;

AGING; ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; COGNITION; CYTOKINES; DEMENTIA, VASCULAR; HUMANS; INFLAMMATION; STRESS, PSYCHOLOGICAL;

EID: 0036901234     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2002.50619.x     Document Type: Article

References (275)

1. Hasegawa Y, Sawada M, Ozaki N et al. Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. Gerontology 2000;46: 185-188.
2. Papanicolaou D, Wilder RL, Manolagas SC et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-137.
3. Kronfol Z, Remick DG. Cytokines and the brain: Implications for clinical psychiatry. Am J Psychiatry 2000;157:683-694.
4. Campbell IL. Transgenic mice and cytokine actions in the brain: Bridging the gap between structural and functional neuropathology. Brain Res Brain Res Rev 1998;26:327-336.
5. Peterson PK, Chao CC, Carson P et al. Levels of tumor necrosis factor alpha, interleukin-6, interleukin-10, and transforming growth factor beta are normal in the serum of the healthy elderly. Clin Infect Dis 1994;19:1158-1159.
6. Ershler WB. Interleukin-6: A cytokine for gerontologists. J Am Geriatr Soc 1993;41:176-181.
7. Wei J, Xu H, Davies JL et al. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992;51:1253-1956.
8. Hager K, Machein U, Krieger S et al. Interleukin 6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 1994;15: 771-772.
9. Roubenoff R, Harris TB, Abad LW et al. Monocyte cytokine production in an elderly population. Effect of age and inflammation. J Gerontol A Biol Sci Med Sci 1998;53A:M20-M26.
10. Sempowski GD, Hale LP, Sundy JS et al. Leukemia inhibitory factor, oncostatin M, IL-6 and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J Immunol 2000; 164:2180-2187.
11. Bruunsgaard H, Andersen-Ranberg K, Jeune B et al. A high plasma concentration of TNF-α is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999;54A:M357-M364.
12. Straub RH, Konecha L, Hrach S et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: Possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998;83:2012-2017.
13. Neumann A, Schinzel R, Palm D et al. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett 1999;453:283-287.
14. Cohen HJ, Pieper CF, Harris T et al. The association of plasma IL-6 levels with functional disability in community dwelling elderly. J Gerontol A Biol Sci Med Sci 1997;52A:M201-M208.
15. Harris TB, Ferrucci L, Tracy RP et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-512.
16. Ferrucci L, Harris TB, Guralnik JM et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999;47:639-646.
17. Mooradian AD, Reed RL, Osterweil D et al. Detectable serum levels of tumor necrosis factor alpha may predicr early mortality in elderly institutionalized patients. J Am Geriatr Soc 1991;39:891-894.
18. Thomas VS, Rockwood K, McDowell I. Multidimensionality in instrumental and basic activities of daily living. J Clin Epidemiol 1998;51:315-321.
19. Weaver J, Seeman T. Interleukin-6 as a predictor of cognitive function and cognitive decline. J Am Geriatr Soc 2000;48(Suppl. 1):S2.
20. Woodroofe C, Mueller W, Ruether U. Long term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol 1992;11:587-592.
21. Böttinger EP, Letterio JJ, Roberts AB. Biology of TGF-β in knockout and transgenic mouse models. Kidney Int 1997;51:1355-1360.
22. Licinio J, Kling MA, Hauser P. Cytokines and brain function: Relevance to interferon-α-induced mood and cognitive changes. Semin Oncol 1998; 25(Suppl. 1):30-38.
23. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999;461:199-233.
24. Dunn AJ, Swiergiel AH. The role of cytokines in infection-related behavior. Ann N Y Acad Sci 1998;840:577-585.
25. Connor TJ, Leonard BE. Depression, stress and immunological activation: The role of cytokines in depressive disorders. Life Sci 1998;62:583-606.
26. Dantzer R, Bluthé RM, Layé S et al. Cytokines and sickness behavior. Ann N Y Acad Sci 1998;840:586-590.
27. Dunn AJ. Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: Comparison with interleukin-1. J Pharmacol Exp Ther 1992;261:964-969.
28. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993;47: 169-176.
29. Gutierrez EG, Banks WA, Kastin AJ. Blood-borne interleukin-1 receptor antagonist crosses the blood brain barrier. J Neuroimmunol 1994;55: 153-160.
30. Maier SF, Goehler LE, Fleshner M et al. The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci 1998;840:289-300.
31. Wong ML, Bongiorno PB, Al-Shekhlee A et al. IL-1 beta, IL-1 receptor type 1 and iNOS gene expression in rat brain vascularure and perivascular areas. Neuroreport 1996;7:2445-2448.
32. Anthony DC, Bolton SJ, Fearn S et al. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 1997;120:435-444.
33. Hickey WF. P selectin, pioneer cells and the path to inflammation. Brain 2000;123:1073-1074.
34. Ek M, Kurosawa M, Lundeberg T et al. Activation of vagal afferents after intravenous injection of interleukin-1β: Role of endogenous prostaglandins. J Neurosci 1998;18:9471-9479.
35. Goehler LE, Gaykema RP, Nguyen KT et al. Interleukin-1β in immune cells of the abdominal vagus nerve: A link between the immune and nervous sytems? J Neurosci 1999;19:2799-2806.
36. Sehic E, Blatteis CM. Blockade of lipopolysaccharide-induced fever by subdiaphragmatic vagotomy in guinea pigs. Brain Res 1996;726:160-166.
37. Bret-Dibat JL, Bluthé RM, Kent S et al. Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism. Brain Behav Immun 1995;9:242-246.
38. Layé S, Bluthé RM, Kent S et al. Subdiaphragmatic vagotomy blocks induction of IL-1 mRNA in mice brain in response to peripheral LPS. Am J Physiol 1995;268:R1327-R1331.
39. Hansen MK, Taishi P, Chen Z et al. Vagotomy blocks the induction of interleukin-1β (IL-1β) mRNA in the brain of rats in response to systemic IL-1β. J Neurosci 1998;18:2247-2253.
40. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 1998;9:259-275.
41. Vitkovic L, Boackaert J, Jacque C. Inflammatory cytokines: Neuromodulators in normal brain? J Neurochem 2000;74:457-471.
42. Mohankumar PS, Thyagarajan S, Quadri SK. Interleukin-1 stimulates the release of dopamine and dihydroxyphenylacetic acid from the hyporhalamus in vivo. Life Sci 1991;48:925-930.
43. Shintani F, Kanba S, Nakaki T et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and seroronin in the rat anterior hypothalamus. J Neurosci 1993;13:3574-3581.
44. Linthorst AC, Flachskamm C, Muller-Preuss P et al. Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: An in vivo microdialysis study. J Neurosci 1995;15:2920-2934.
45. Merali Z, Lacosta S, Anisman H. Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: A regional microdialysis study. Brain Res 1997;761:225-235.
46. Sheng JG, Mrak RE, Griffin WS. Enlarged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain. Acta Neuropathol 1998;95:229-234.
47. Ye SM, Johnson RW. Increased interleukin-6 expression by microglia from brain of aged mice. J Neuroimmunol 1999;93:139-148.
48. Gayle D, Ilyin SE, Romanovitch AE. Basal and IL-1β-stimulated cytokine and neuropeptide mRNA expression in brain regions of young and old Long-Evans rats. Mol Brain Res 1999;70:92-100.
49. Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nat Genet 2000;25:294-297.
50. Finch CE, Morgan TE, Rozovsky I et al. Microglia and aging in the brain. In: Streit WJ, ed. Microglia in the Degenerating and Regenerating CNS. New York: Springer-Verlag, Inc., 2002.
51. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996;273:59-63.
52. Finch CE, Morgan TE. Food restriction and brain aging. In: Mattson M, ed. The Aging Brain (Advances in Gerontology). Adv Cell Aging Gerontol 1997;2:279-298.
53. Finch CE, Longo V, Miyao A et al. Amyloids, inflammatory mechanisms in Alzheimer disease, and aging. In: Chesselet MF, ed. Molecular Mechanisms in Neurodegenerative Diseases, 1st Ed. Towota, NJ: Humana Press, 2001, pp 87-110.
54. Klebanov S, Diais S, Stavinoha WB et al. Hyperadrenocorticism, attenuated inflammation, and the life-prolonging action of food restriction in mice. J Gerontol A Biol Sci Med Sci 1995;50A:B79-B82.
55. Zhao B, Schwartz JP. Involvements of cytokines in normal CNS development and neurological diseases: Recent progress and perspectives. J Neurosci Res 1998;52:7-16.
56. Jonakait GM. Cytokines in neuronal development. Adv Pharmacol 1997; 37:35-53.
57. Toulmond S, Vige X, Fage D et al. Local infusion of interleukin-6 attenuates the neurotoxic effects of NMDA on rat striatal cholinergic neurons. Neurosci Lett 1992;144:49-52.
58. Veerhuis R, Janssen I, Hoozemans JJ et al. Cytokines associated with amyloid plaques in Alzheimer disease brains stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C-1 inhibitor. Exp Neurol 1999;160:289-299.
59. Giulian D, Ingeman JE. Colony-stimulating factors as promotors of ameboid microglia. J Neurosci 1988;8:4707-4717.
60. Giulian D, Woodward J, Young DG et al. Interleukin-1 injection into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1988;8:2485-2490.
61. Lieberman AP, Pitha PM, Shin HS et al. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A 1989;86:6348-6352.
62. Jeohn GH, Kong LY, Wilson B et al. Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol 1998;85:1-10.
63. McGeer PL, McGeer EG. Inflammation of the brain in Alzheimer's disease: Implications for therapy. J Leukoc Biol 1999;6S:409-415.
64. Lemke R, Hartlage-Rübsamen M, Schliebs R. Differential injury-dependent glial expression of interleukins-1α,β, and interleukin-6 in rat brain. Glia 1999;27:75-87.
65. Griffin WS, Sheng JG, Royston MC et al. Glial-neuronal interactions in Alzheimer's disease. The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998;8:65-72.
66. Wallace MN, Geddes JG, Farquhar DA et al. Nitric oxide synthase in reactive astrocytes adjacent to β-amyloid plaques. Exp Neurol 1997;144:266-272.
67. Chao CC, Hu S, Molitor TW et al. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992;149:2736-2741.
68. Hu S, Peterson PL, Chao CC. Cytokine-mediated neuronal apoptosis. Neurochem Int 1997;30:427-431.
69. Bruce-Keller AJ. Microglial-neuronal interactions in synaptic damage and recovery. J Neurosci Res 1999;58:191-201.
70. Rothwell NJ. Cytokines - Killers in the brain? J Physiol 1999;514:3-17.
71. Raine CS. Inflammation in Alzheimer's disease: A view from the periphery. Neurobiol Aging 2000;21:437-440.
72. Yabuuchi K, Minami M, Katsumata S et al. Localization of type 1 interleukin-1 receptor mRNA in the rat brain. Mol Brain Res 1994;27:27-36.
73. Wong ML, Licinio J. Localization of interleukin 1 type 1 receptor mRNA in rat brain. Neuroimmunomodulation 1994;1:110-115.
74. Arvin B, Neville LF, Barone FC et al. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996;20:445-452.
75. Ganter S, Norrhoff H, Mannel D et al. Growth control of cultured microglia. J Neurosci Res 1992;33:218-230.
76. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992;29:243-246.
77. Müller N, Ackerheil M. Psychoneuroimmunology and the cytokine action in the CNS. Implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33.
78. Zalcman S, Green-Johnson JM, Murray L et al. Cytokine-specific central monoamine alterations induced by interleukin-1-2, and -6. Brain Res 1994; 643:40-49.
79. Li Y, Liu L, Kang J et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000;20:149-155.
80. Rada P, Mark GP, Vitek MP. Interleukin-1β decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Res 1991;15:287-290.
81. Casamenti F, Prosperi C, Scali C et al. Interleukin-1β activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: Implications for Alzheimer's disease. Neuroscience 1999;91:831-842.
82. Pearson V, Rothwell NJ, Toulmond S. Excitotoxic brain damage in the rat induces IL-1 protein in microglia and astrocytes: Correlation with the progression of cell death. Glia 1999;25:311-323.
83. Luk WP, Zhang Y, White TD et al. Adenosine. A mediator of interleukin-1β-induced hippocampal synaptic inhibition. J Neurosci 1999;19: 4238-4244.
84. Huang TL, O'Banion MK. Interleukin-1β and tumor necrosis factor-alpha suppress dexamethasone induction of glutamine synthetase in primary mouse astrocytes. J Neurochem 1998;71:1436-1442.
85. Friedlander RM, Gagliardini V, Rotello RJ et al. Functional role of interleukin 1 beta (IL-1 beta) in IL-1 beta-converting enzyme-mediated apoptosis. J Exp Med 1996;184:717-724.
86. Kuida K, Lippke JA, Ku G et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995;267: 2000-2003.
87. Yuan J, Shaham S, Ledoux S et al. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta converting enzyme. Cell 1993;75:641-652.
88. Spadaro F, Dunn AJ. Intracerebroventricular administration of interleukin-1 to mice alters investigation of stimuli in a novel environment. Brain Behav Immun 1990;4:308-322.
89. Crestani F, Seguy F, Dantzer R. Behavioral effects of peripherally injected interleukin-1: Role of prostaglandins. Brain Res 1991;542:330-335.
90. Yirmiya R, Avitsur R, Donchin O et al. Interleukin-1 inhibits sexual behavior in female but not male rats. Brain Behav Immun 1995;9:220-233.
91. Krueger JM, Fang J, Taishi P et al. Sleep. A physiologic role for IL-1 beta and TNF-alpha. Ann N Y Acad Sci 1998;856:148-159.
92. Plata-Salaman CR, Oomura Y, Kai Y. Tumor necrosis factor and interleukin-1 beta: Suppression of food intake by direct action in the central nervous system. Brain Res 1988;448:106-114.
93. Gibertini M. Cytokines and cognitive behavior. Neuroimmunomodulation 1998;5:160-165.
94. Oitzl MS, van Oers H, Schobitz B et al. Interleukin-1 beta, but not interleukin-6, impairs spatial navigation learning. Brain Res 1993;613:160-163.
95. Lynch MA. Age-related impairment in long-term potentiation in the hippocampus. A role for the cytokine, interleukin-1 beta? Prog Neurobiol 1998;56:571-579.
96. Alonso R, Chadeau I, Diorio J et al. Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells. J Neurochem 1993;61:1284-1290.
97. Lapchak PA. A role for interleukin-2 in the regulation of striatal dopaminergic function. Neuroreport 1992;3:165-168.
98. Tancredi V, Zona C, Velotti F et al. Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. Brain Res 1990;525:149-151.
99. Nemni R, Iannaccone S, Quattrini A et al. Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res 1992;591:248-252.
100. Park HJ, Won CK, Pyun KH et al. Interleukin 2 suppresses afferent sensory transmission in the primary somatosensory cortex. Neuroreport 1995;6: 1018-1020.
101. Pace A, Pietrangeli A, Bove L et al. Neurotoxicity of antitumoral IL-2 therapy: Evoked cognitive potentials and brain mapping. Ital J Neurol Sci 1994;15:341-346.
102. Jiang CL, Lu CL. Interleukin-2 and its effects in the central nervous system. Biol Signals Recept 1998;7:148-156.
103. Romano M, Sironi M, Toniatti C et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315-325.
104. Qiu Z, Sweeney DD, Netzeband JG et al. Chronic interleukin-6 alters NMDA receptor-mediated membrane reponses and enhances neurotoxicity in developing CNS neurons. J Neurosci 1998;18:10445-10456.
105. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 acrivates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Merab 1993;77:1690-1694.
106. Loddick SA, Turnbull AV, Rothwell NJ. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1998;18:176-179.
107. Song C, Merali Z, Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 1999;88:823-836.
108. Bianchi M, Ferrario P, Clavenna A et al. Interleukin-6 affects scopolamineinduced amnesia, but not brain amino acid levels in mice. Neuroreport 1997;8:1775-1778.
109. Zhong J, Dietzel ID, Wahle P et al. Sensory impairments and delayed regeneration of sensory axons in IL-6 deficient mice. J Neurosci 1999;19:4305-4313.
110. Heyser CJ, Masliah E, Samimi A et al. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci U S A 1997;94: 1500-1505.
111. Wang YX, Jiang CL, Lu CL et al. Distinct domains of IFNα mediate immune and analgesic effects respectively. J Neuroimmunol 2000;108:64-67.
112. Smith A, Tyrrell D, Coyle K et al. Effects of interferon alpha on performance in man: A preliminary report. Psychopharmacology 1988;96: 414-416.
113. Valentine AD, Meyers CA, Kling MA. Mood and cognitive side effects of interferon-α therapy. Semin Oncol 1998;25:39-47.
114. Ho BT, Huo YY, Lu JG et al. Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha. Pharmacol Biochem Behav 1992;42:57-60.
115. Kalaria RN, Harshbarger-Kelly M, Cohen DL et al. Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Neurobiol Aging 1996;17:687-693.
116. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
117. Luterman JD, Harotunian V, Yemul S et al. Cytokine gene expression as a function of the clinical expression of Alzheimer's disease. Arch Neurol 2000;57:1153-1160.
118. Webster S, Bradt B, Rogers J et al. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem 1997;69:388-398.
119. Klein WL, Krafft GA, Finch CE. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 2001;24:219-224.
120. Fassbender K, Masters C, Beyreuther K. Alzheimer's disease: An inflammatory disease? Neurobiol Aging 2000;21:433-436.
121. Alvarez XA, Franco A, Fernandez-Novoa F et al. Blood levels of histamine, IL-1beta and TNF-alpha in patients with mild to moderate Alzheimer's disease. Mol Chem Neuropathol 1996;29:237-252.
122. Huberman M, Sredni B, Stern L et al. IL-2 and IL-6 secretion in dementia: Correlation with type and severity of disease. J Neurol Sci 1995;130:161-164.
123. Singh VK, Guthikonda P. Circulating cytokines in Alzheimer's disease. J Psychiatr Res 1997;31:657-660.
124. Bonaccorso S, Lin A, Song C et al. Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milano) 1998;10:316-323.
125. Fillit H, Ding WH, Buee L et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991;129:318-320.
126. Bauer J, Ganter U, Strauss S et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol 1992;143:650-657.
127. Strauss S, Bauer J, Ganter U et al. Detection of interleukin-6 and α-2 macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 1992;66:223-230.
128. Lombardi VR, García M, Rey L et al. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals. J Neuroimmunol 1999; 97:163-171.
129. Van Duijn CM, Hofman A, Nagelkerkern L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci Lett 1990; 108:350-354.
130. Angelis P, Scharf S, Mander A. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci Lett 1998;244:106-108.
131. Cacabelos R, Barquero M, Garcia P et al. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Meth Find Exp Clin Pharmacol 1991;13:455-458.
132. Hampel H, Schoen D, Schwartz MJ et al. IL-6 is not altered in cerebrospinal fluid of first degree relatives and patients with Alzheimer's disease. Neurosci Lett 1997;228:143-146.
133. Marz P, Heese K; Hock C et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 1997;239:29-32.
134. Licastro F, Pedrini S, Caputo L et al. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain? J Neuroimmunol 2000;103:97-102.
135. Leblhuber F, Walli J, Demel U et al. Increased serum neopterin concentrations in patients with Alzheimer's disease. Clin Chem Lab Med 1999;37: 429-431.
136. Lanzrein AS, Johnston CM, Perry VH et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer's disease: Interleukin-1β, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-α the soluble tumor necrosis factor receptors I and II, and α1-antichymotrypsin. Alzheimer Dis Assoc Disord 1998;12:215-227.
137. De Simoni MG, Luigi A, Gemma L et al. Modulation of systemic interleukin-6 induction by systemic interleukin-1. Am J Physiol 1993;265:739-742.
138. Xiao E, Xia L, Ferin M et al. Intracerebroventricular injection of interleukin-1 stimulates the release of high levels of interleukin-6 and interleukin-1-receptor antagonist into the peripheral blood in the primate. J Neuroimmunol 1999;97:70-76.
139. Zanjani H, Lanzrein AS, McKeel DQ et al. Clusterin and complement components C1q and C3 deposits are increased at very early stages of Alzheimer's disease. Soc Neurosci 1999;25:1102.
140. Morris JC, Storandt M, Miller JP et al. Mild cognitive impairment represents early stage Alzheimer disease. Arch Neurol 2001;58:397-405.
141. Mufson EJ, Chen EY, Cochran EJ et al. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999;158: 469-490.
142. Tronsco JC, Cataldo AM, Nixon RA et al. Neuropathology of preclinical and clinical late-onset Alzheimer's disease. Ann Neurol 1998;43:673-676.
143. Papassotiropoulos A, Bagli M, Jessen F et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer disease. Ann Neurol 1999;45:666-668.
144. Grimaldi LM, Casadei VM, Ferri C et al. Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism. Ann Neurol 2000;47:361-365.
145. Nicoll JA, Mrak RE, Graham DI et al. Association of interleukin-1 gene polymorphisms with Alzheimer disease. Ann Neurol 2000;47:365-368.
146. Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. Nature 1989;341:226-230.
147. Mackic JB, Weiss MH, Miao W et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998;70:210-215.
148. Kuo YM, Kokjohn TA, Watson MD et al. Elevated Aβ42 in skeletal muscle of Alzheimer's disease patients suggests peripheral alterations of AβPP metabolism. Am J Pathol 2000;156:797-805.
149. Wen GY, Wisniewski HM, Blondal H et al. Presence of non-fibrillar amyloid beta protein in skin biopsies of Alzheimer's disease (AD), Down's syndrome and non-AD normal persons. Acta Neuropathol (Berl) 1994;88:201-206.
150. Di Luca M, Pastorino L, Bianchetti A et al. Differential level of platelet amyloid β precursor protein isoforms: An early marker for Alzheimer's disease. Arch Neurol 1998;55:1195-1200.
151. Rosenberg RN, Baskin F, Fosmire JA et al. Altered amyloid protein processing in platelets of patients with Alzheimer's disease. Arch Neurol 1997; 54:139-144.
152. Finch CE, Longo V, Miyao A et al. Amyloids, inflammatory mechanisms in Alzheimer's disease, and aging. In: Chesselet MF, ed. Molecular Mechanisms in Neurodegenerative Diseases, 1st Ed. Towota, NJ: Humana Press, 2001, pp 87-110.
153. Bertozzi B, Barbisoni P, Franzoni S et al. Association of chronic non-steroidal anti-inflammatory drug use and cognitive decline in non-demented elderly patients admitted to a Geriatric Evaluation and Rehabilitation Unit. Arch Gerontol Geriatr 1996;23:71-79.
154. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47:425-432.
155. Rozzini R, Ferrucci L, Losonczy K et al. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996;44:1025-1029
156. Stewart WF, Kawas K, Corrada M et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-632.
157. Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
158. Anthony JC, Breitner JCS, Zandi PP et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists. The Cache County Study. Neurology 2000;54:2066-2071.
159. In't Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's Disease. N Engl J Med 2001;345: 1515-1521.
160. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-632.
161. Breitner JCS, Gau BA, Welsh KA et al. Inverse association of antiinflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 1994;44:227-232.
162. Canadian study of health and aging. Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
163. Doraiswamy PM, Krischen A, Stallone F et al. NSAIDs and cognition in Alzheimer's disease. Neurology 1996;46:1194.
164. Breitner JC, Zandi P. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med 2001;345:1567-1568.
165. Broe GA, Grayson GA, Creasey HM et al. Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch Neurol 2000;57:1586-1591.
166. Hanlon JT, Schmader KE, Landerman LR et al. Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. Ann Epidemiol 1997;7:87-94.
167. Saag KG, Rubenstein LM, Christchilles EA et al. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995;22: 2142-2147.
168. Thornton TL. Delirium associated with sulindac. JAMA 1980;243: 1630-1631.
169. Gotz V. Paranoid psychosis with indomethacin. BMJ 1978;1:49.
170. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982;25:1013-1015.
171. Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414:212-216.
172. Zandi PP, Breitner JC. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001;22:811-817.
173. Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20:5709-5714.
174. Blom MA, van Twillert MG, de Vries SC et al. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes. The involvement of prostaglandin E2. Brain Res 1997;777:210-218.
175. Combs CK, Johnson DE, Karlo JC et al. Inflammatory mechanisms in Alzheimer's disease. Inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 2000;20:558-567.
176. Heneka MT, Feinstein DL, Galea E et al. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 1999;100:156-168.
177. Weiss DJ, Rashid J. The sepsis-coagulant axis: A review. J Vet Intern Med 1998;12:317-324.
178. Locker GJ, Kapiotis S, Veitl M et al. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br J Haematol 1999;105:912-919.
179. Kanabrocki EL, Sothern RB, Messmore HL et al. Circadian relationships among levels of plasma fibrinogen, blood platelets, and serum interleukin-6. Clin Appl Thromb Hemost 1999;5:37-42.
180. Libby P, Sukhova G, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(Suppl. 2):9S-12S.
181. Levine JB, Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am 1995;24:633-646.
182. Iversen PO, Nicolaysen A, Kvernebo K et al. Human cytokines modulate arterial vascular tone via endothelial receptors. Pflugers Arch 1999;439:93-100.
183. Felten DL, Felten SY, Belleinger DL et al. Noradrenergic sympathetic neural interactions with the immune system: Structure and function. Immunol Rev 1987;100:225-260.
184. Felten SY, Felten DL. Innervation of lymphoid tissue. In: Ader R, Felten DL, Cohen N, eds. Psychoneuroimmunology, 2nd Ed. New York: Academic Press, 1991, pp 27-70.
185. Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. N Engl J Med 1991;325:606-612.
186. Glaser R, Kiecolt-Glaser J, Bonneau R et al. Stress induced modulation of the immune response to recombinant hepatitis B vaccine. Psychosom Med 1992;54:22-29.
187. Irwin M. Psychoneuroimmunology and depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1995, pp 983-998.
188. Weizman R, Bessler H, et al. Stress and immunity - An overview. In: Plotnikoff NP, Faith RE, Murgo AJ et al., eds. Cytokines: Stress and Immunity. Boca Raton, FL: CRC Press, 1999, pp 1-16.
189. LeMay LG, Vander AJ, Kluger MJ. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol Behav 1990;47:957-961.
190. Takaki A, Huang Q, Somogyvari-Vigh A et al. Immobilization stress may increase plasma interleukin-6 via central and peripheral catecholamines. Neuroimmunomodulation 1994;1:335-342.
191. Zhou D, Kusnecov AW, Shurin MR et al. Exposure to physical and psychological stressors elevates plasma interleukin-6: Relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 1993;133: 2523-2530.
192. Minami M, Kuraishi Y, Yamaguchi T et al. Immobilization stress induces interleukin-1 beta mRNA in the rat hypothalamus. Neurosci Lett 1991; 123:254-256.
193. Suzuki E, Shintani F, Kanba S et al. Immobilization stress increases mRNA levels of interleukin-1 receptor antagonist in various rat brain regions. Cell Mol Neurobiol 1997;17:557-562.
194. Besedovsky HO, Del Ray A, Sorkin E et al. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986;233: 652-654.
195. Shintani F, Nakaki T, Kanba S et al. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. Neuroscience 1995; 15:1961-1970.
196. Weiss JM, Quan N, Sundar SK. Widespread activation and consequences of interleukin-1 in the brain. Ann N Y Acad Sci 1994;741:338-357.
197. Berkenbosch F, Van Oers J, Del Ray A et al. Corticotrophin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987; 238:524-526.
198. Ericsson A, Arias C, Sawchenko PE. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 1997;17:7166-7167.
199. Sundar SK, Cierpal MA, Kilts C et al. Brain IL-1 induced immunosuppression occurs through activation of both pituitary-adrenal axis and sympathetic nervous system by corticotrophin-releasing factor. J Neurosci 1990; 10:3701-3706.
200. Raber J, Bloom FE. IL-2 induces vasopressin release from the hypothalamus and the amygdala: Role of nitric oxide-mediated signaling. J Neurosci 1994;14:6187-6195.
201. Tachikawa E, Itho K, Harada K et al. Effects of interferons on cortisol production in bovine adrenal fasciculata cells stimulated by adrenocorticotropin. J Pharm Pharmacol 1999;51:465-473.
202. Kidron D, Saphier D, Ovadia H et al. Central administration of immunomodulatory factors alters neural activity and adrenocortical secretion. Brain Behav Immun 1989;3:15-27.
203. Propes MJ, Johnson RW. Role of corticosterone in the behavioral effects of central interleukin-1 beta. Physiol Behav 1997;61:7-13.
204. Nguyen V, Walker WS, Benveniste EN. Post-transcriptional inhibition of CD40 gene expression in microglia by TGF-β. Eur J Immunol 1998;28: 2537-2548.
205. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15:74-80.
206. Wiegers GJ, Reul JM. Induction of cytokine receptors by glucocorticoids: Functional and pathological significance. Trends Pharmacol Sci 1998;19: 317-321.
207. Crook TH, Miller NW. The challenge of Alzheimer's disease. Am Psychol 1985;40:1245-1250.
208. Esterling BA, Kiecolt-Glaser JK, Bodnar JC et al. Chronic stress, social support, and persistent alterations in the natural killer cell response to cytokines in older adults. Health Psychol 1994;13:291-298.
209. Kiecolt-Glaser JK, Marucha PT, Malarkey WB et al. Slowing of wound healing by psychological stress. Lancet 1996;346:1194-1196.
210. Kiecolt-Glaser JK, Dura JR, Speicher CE et al. Spousal caregivers of dementia victims: Longitudinal changes in immunity and health. Psychosom Med 1991;53:345-362.
211. Lutgendorf SK, Garand L, Buckwalter K et al. Life stress and elevated IL-6 in healthy elderly women. J Gerontol A Biol Sci Med Sci 1999;54A:M1-M6.
212. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(Suppl. 6):4-6.
213. Cunningham ET, de Souza EB. Interleukin 1 receptors in the brain and endocrine tissue. Immunol Today 1996;14:171-176.
214. Ramamoorthy S, Ramamoorthy JD, Pradad P et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun 1995;216:560-567.
215. Bateman A, Singh A, Kral T et al. The immune-hypothalamic pituitary axis. Endocr Rev 1989;10:92-112.
216. Smith RS. The macrophage theory of depression. Med Hypotheses 1991; 35:298-306.
217. Dentino AN, Pieper CF, Rao MK et al. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc 1999;47:6-11.
218. Maes M, Scharpe S, Meltzer HY et al. Increased neopterin and interferongamma secretion and lower availability of 1-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res 1994;54: 143-160.
219. Maes M, Meltzer HY, Bosmans E et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301-309.
220. Maes M, Vandoolaeghe E, Ranjan R et al. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J Affect Disord 1995;36:29-36.
221. Sluzewska A, Rybakowski J, Bosmans E et al. Indicators of immune activation in major depression. Psychiatry Res 1996;64:161-167.
222. Frommberger UH, Bauer J, Hasselbauer P et al. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: Comparisons between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247: 228-233.
223. Lee SW, Tsou A, Chan H et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc Natl Acad Sci U S A 1988;85:1204-1208.
224. Connor TJ, Song C, Leonard BE et al. An assessment of the effects of central interleukin-1β-2-6 and tumor necrosis factor-α administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 1998;84:923-933.
225. Matthews DA, McCullough ME, Larson DB et al. Religious commitment and health status: A review of the research and implications for family medicine. Arch Fam Med 1998;7:118-124.
226. Helm HM, Hays JC, Flint EP et al. Does private religious activity prolong survival? A six-year follow-up study of 3,851 older adults. J Gerontol A Biol Sci Med Sci 2000;55A:M400-M405.
227. Koenig HG, Cohen HJ, George LK et al. Attendance at religious services, interleukin-6, and other biological parameters of immune function in older adults. Int J Psychiatry Med 1997;27:233-250.
228. George LK. Social factors and the onset and outcome of depression. In: Schaie KW, Blazer D, House JS, eds. Aging, Health Behaviors, and Health Outcomes. Hillsdale, NJ: Lawrence Erlbaum Associates, 1992, pp 137-159.
229. Yeh SS, Schuster MW. Geriatric cachexia. The role of cytokines. Am J Clin Nutr 1999;70:183-197.
230. Plata-Salaman CR, Sonti G, Borkoski JP et al. Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Physiol Behav 1996;60:867-875.
231. Malek-Ahmadi P. Neuropsychiatric aspects of cytokines research: An overview. Neurosci Biobehav Rev 1996;20:359-365.
232. White DW, Tartaglia LA. Leptin and body weight regulation by a cytokine receptor. Cytokine Growth Factor Rev 1996;7:303-309.
233. Nourhashémi F, Gillette-Guyonnet S, Andrieu S et al. Alzheimer's disease: Protective factors. Am J Clin Nutr 2000;71(Suppl.):643S-649S.
234. Selhub J, Bagley LC, Miller J et al. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71(Suppl.):614S-620S.
235. Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983; 249:2917-2921.
236. Boushey CJ, Beresford SA, Omenn GS et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274:1049-1057.
237. Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the aging brain in mice. Nature Genet 2000;25:294-297.
238. Lee J, Duan W, Long JM et al. Dietary restriction increases the number of newly generated neural cells and induces BDNF expression in the dentate gyrus of rats. J Mol Neurosci 2000;15:99-108.
239. Takahashi S, Kapas L, Fang J et al. Somnogenic relationships between tumor necrosis factor and interleukin-1. Am J Physiol 1999;276:R132-R140.
240. Spath-Schwalbe E, Lange T, Perras B et al. Interferon-alpha acutely impairs sleep in healthy humans. Cytokine 2000;12:518-521.
241. Vgontzas AN, Papanicolaou DA, Bixler EO et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999; 84:2603-2607.
242. Kubota T, Fang J, Kushikata T et al. Interleukin-13 and transforming growth factor-beta1 inhibit spontaneous sleep in rabbits. Am J Physiol 2000;279:R786-R792.
243. Kushikata T, Fang J, Wang Y et al. Interleukin-4 inhibits spontaneous sleep in rabbits. Am J Physiol 1998;275:R1185-R1191.
244. Kushikata T, Fang J, Krueger JM. Interleukin-10 inhibits spontaneous sleep in rabbits. J Interferon Cytokine Res 1999;19:1025-1030.
245. Spath-Schwalbe E, Hansen K, Schmidt F et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573-1579.
246. Kimura M, Kodama T, Aguila MC et al. Granulocyte-macrophage colony-stimulating factor modulates rapid eye movement (REM) sleep and non-REM sleep in rats. J Neurosci 2000;20:5544-5551.
247. Pilcher JJ, Walters AS. How sleep deprivation affects psychological variables related to college students' cognitive performance. J Am Coll Health 1997;46:121-126.
248. McCarthy ME, Waters WF. Decreased attentional responsivity during sleep deprivation. Orienting response latency, amplitude, and habituation. Sleep 1997;20:115-123.
249. Corsi-Cabrera M, Arce C, Del Rio-Portilla IY et al. Amplitude reduction in visual event-related potentials as a function of sleep deprivation. Sleep 1999;22:181-189.
250. Inouye SK, Bogardus ST Jr, Charpentier PA et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999;340:669-676.
251. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-229.
252. Cooper NR, Kalaria RN, McGeer PL et al. Neuroinflammation Working Group. Key issues in Alzheimer's disease inflammation. Neurobiol Aging 2000;21:451-453.
253. Sanderson KL, Raghupathi R, Saatman KE et al. Interleukin-1 receptor antagonist attenuates regional neuronal cell death and cognitive dysfunction after experimental brain injury. J Cereb Blood Flow Metab 1999;19:1118-1125.
254. Yamada H, Mizumo S, Horai R et al. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab Invest 2000;80:759-767.
255. Herx LM, Rivest S, Yong VW. Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J Immunol 2000;165:2232-2239.
256. Green P, Simpkins JW. Neuroprotective effects of estrogens: Potential mechanisms of action. Int J Dev Neurosci 2000;18:347-358.
257. Sherwin BB, Carlson LE. Estrogen and memory. J Soc Obstet Gyn Can 1997;19:7-13.
258. Schmidt R, Fazekas F, Reinhart B et al. Estrogen replacement therapy in older women. A neuropsychological and brain MRI study. J Am Geriatr Soc 1996;44:1307-1313.
259. Morishita M, Miyagi M, Iwamoto Y. Effects of sex hormones on production of interleukin-1 by human peripheral monocytes. J Periodontol 1999; 70:757-760.
260. Kikuchi N, Urabe M, Iwasa K et al. Atheroprotective effect of estriol and estrone sulfate on human vascular smooth muscle cells. J Steroid Biochem Mol Biol 2000;72:71-78.
261. Bruce-Keller AJ, Keeling JL, Keller JN et al. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 2000;141:3646-3656.
262. Dodel RCY, Bales KR et al. Sodium salicylate and 17beta-estradiol attenuate nuclear transcription factor NF-kappaß translocation in cultured rat astroglial cultures following exposure to amyloid A beta (140) and lipopolysaccharides. J Neurochem 1999;73:1453-1460.
263. Li R, Shen Y, Yang LB et al. Estrogen enhances uptake of amyloid betaprotein by microglia derived from the human cortex. J Neurochem 2000; 75:1447-1454.
264. Straub RH, Konecha L, Hrach S et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: Possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998;83:2012-2017.
265. Danenberg HD, Ben-Yehuda A, Rones-Zakay Z et al. Dehydroepiandrosterone reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 1995;13:1445-1448.
266. Kipper-Galperin M, Galilly R, Danenberg HD et al. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor α and interleukin-6 in astrocytes. Int J Dev Neurosci 1999;17:765-775.
267. Huppert FA, Van Niekerk JK, Herbert J. Dehydroepiandrosterone (DHEA) supplementation for cognition and well-being. Cochrane Database Syst Rev 2000;(2):CD000304. Review.
268. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71(Suppl. 1):343S-348S.
269. Sadeghi S, Wallace FA, Calder PC. Dietary lipids modify the cytokine response to bacterial lipopolysaccharide in mice. Immunology 1999;96: 404-410.
270. Major DE, Kesslak JP, Cotman CW et al. Life-long dietary restriction attenuates age-related increases in hippocampal glial fibrillary acidic protein mRNA. Neurobiol Aging 1997;18:523-526.
271. Morgan TE, Xie Z, Goldsmith S et al. The mosaic of brain glial hyperactivity during normal ageing and its artenuation by food restriction. Neuroscience 1999;89:687-699.
272. Hassmen P, Koivula N. Mood, physical working capacity and cognitive performance in the elderly as related to physical activity. Aging (Milano) 1997;9:136-142.
273. Radák Z, Kaneko T, Tahara S et al. Regular exercise improves cognitive function and decreases oxidative damage in rat brain. Neurochem Int 2001;38:17-23.
274. Smith JK, Dykes R, Douglas JE et al. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999;281:1722-1727.
275. Blumenthal JA, Babyak MA, Moore KA et al. Effects of exercise training on older patients with major depression. Arch Intern Med 1999;159:2349-2356.